Targeting TFRC has shown promising antitumor effects, as demonstrated by Shimosaki et al., who developed a human IgG monoclonal antibody against TFR1, significantly suppressing the growth of HTLV-1-associated adult T-cell leukemia/lymphoma cells 41. Here, TFRC is linked to lymphoma.